Newborn Screening Market Size

Newborn Screening Market Size

Newborn Screening Market size was valued at USD 950.5 million in 2023 and is estimated to grow at 7.7% CAGR from 2024 to 2032 due to the rising incidence of genetic and metabolic diseases.

The growing burden of congenital disorders detected at birth is driving the demand for several screening tests. Hospitals and healthcare providers are increasingly adopting advanced screening technologies to identify these disorders early for ensuring timely intervention and treatment.
 

Rapid technological advancements are improving the accuracy and efficiency of screening methods. Moreover, expanded screening programs will enhance the ability to detect and manage newborn disorders effectively. For instance, in March 2024, WHO reported that the first month is the most vulnerable for child survival, with 2.3 million newborns dead in 2022, subsequently highlighting the critical need for effective newborn screening to improve early detection and intervention.
 

The rise in government initiatives and policies for mandating newborn screening in various regions is supporting the market growth. These mandates are driving healthcare providers to adopt comprehensive screening programs for ensuring early detection and intervention for genetic, metabolic, and congenital disorders. As governments continue to recognize the importance of early diagnosis in improving child health outcomes, they are implementing and reinforcing these policies. This ongoing support through government policies will expand the reach and effectiveness of newborn screening programs to enhance public health. For instance, the Alabama Bureau of Clinical Laboratories (BCL) is conducting all newborn blood screenings in Alabama and testing around 60,000 babies annually and handling 150,000 specimens.
 

However, limited infrastructure and the shortage of skilled professionals are impeding newborn screening efforts. These challenges are continuing to hamper the widespread implementation and effectiveness of screening programs. Without adequate resources and expertise, early detection and intervention will remain compromised, potentially leading to preventable health complications and increased infant mortality rates, restricting the industry expansion to some extent.